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Objectives. We sought to study the efficacy of “triple” therapy
with digoxin, diuretic and angiotensin-converting enzyme inhibi-
tor (ACEI) compared to other combinations of these drugs in
patients with symptomatic left ventricular systolic dysfunction.
Background. Controversy continues concerning the role of
combining digoxin with diuretic and ACEI in the initial manage-
ment of patients with heart failure.
Methods. The study utilized data from two studies of digoxin
efficacy: Prospective Randomized Study of Ventricular Function
and Efficacy of Digoxin (PROVED) and Randomized Assessment
of Digoxin and Inhibitors of Angiotensin-Converting Enzyme
(RADIANCE). Worsening heart failure defined as augmentation
of heart failure therapy or an emergency room visit or hospital-
ization for increased heart failure was the main outcome measure.
Results. A total of 266 patients comprising the four treatment
groups of the combined PROVED (diuretic alone or digoxin and
diuretic) and RADIANCE (ACEI and diuretic, or digoxin, diuretic
and ACEI) trials were analyzed. Worsening heart failure occurred
in only 4 of the 85 patients who continued digoxin, diuretic and
ACEI therapy (4.7%) compared to 18 of the 42 patients (19%) on
digoxin and diuretic therapy (p 5 0.009), to 23 of the 93 patients
(25%) on ACEI and diuretic therapy (p 5 0.001) and to 18 of the
46 patients (39%) on diuretic alone (p < 0.001). Life table and
multivariate analysis also demonstrated that worsening heart
failure was least likely in patients treated with triple therapy (p <
0.01 vs. all other groups).
Conclusion. Pending definitive, prospective clinical trials, our
results argue for triple therapy as the initial management of
patients with symptomatic heart failure due to systolic dysfunc-
tion.
(J Am Coll Cardiol 1998;32:686–92)
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A number of well-designed and conducted clinical trials have
demonstrated the benefits of individual pharmacologic agents
in the treatment of heart failure (1). In the setting of systolic
dysfunction, administration of enalapril reduced morbidity and
mortality in symptomatic patients and attenuated the risk of
developing heart failure in patients with few or no symptoms
See page 693.
(2,3). As a consequence of these favorable results, clinical
guidelines have advocated a stepped-care approach to phar-
macotherapy of patients with heart failure due to left ventric-
ular systolic dysfunction (4). Recommendations favor com-
mencing therapy with an angiotensin-converting enzyme
inhibitor (ACEI) and, if necessary, adding diuretic rather than
“triple” therapy treatment with digoxin, ACEI and diuretic (5).
Other interpretations of the available clinical data are
possible. Dissimilar and potentially complementary mecha-
nisms of action argue for combination therapy with digoxin and
ACEI (6–15). Heart failure trials of ACEI, including the
treatment arm of the Studies of Left Ventricular Dysfunction,
utilized digoxin and diuretic as background therapy in many
patients. Prospective Randomized Study of Ventricular Func-
tion and Efficacy of Digoxin (PROVED) (16) and Randomized
Assessment of Digoxin and Inhibitors of Angiotensin-
Converting Enzyme (RADIANCE) (17), two placebo-
controlled withdrawal trials, provided evidence of digitalis
efficacy, with or without ACEI, in patients with heart failure
due to systolic dysfunction. The favorable effect of digoxin
administration on the risk of cardiovascular hospitalization
observed in the Digoxin Investigators Group (DIG) study
supports the concept of triple therapy (18) since the majority of
patients in this trial were taking ACEI and diuretic as back-
ground therapy. The public health importance of this issue is
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highlighted by surveys demonstrating the huge cost of treating
decompensated heart failure and community practice patterns
which continue to indicate that many heart failure patients are
treated with diuretic alone while triple therapy is the exception
(19–21).
Although prior studies provide some information concern-
ing the relative merits of triple therapy, data from patients
randomized to this therapy vs. other combinations of digoxin,
ACEI and diuretic are currently unavailable and not likely to
be forthcoming. Lacking such randomized data, we have
turned to two trials of digoxin efficacy, PROVED and
RADIANCE. These two studies had, by design, the same
inclusion and exclusion criteria, methodology and end points
but they differed in the treatments utilized. PROVED com-
pared patients treated with digoxin and diuretic vs. diuretic
alone, while RADIANCE compared patients treated with
diuretic and ACEI to those given digoxin, diuretic and ACEI.
In addition, these trials gathered data concerning the short-
term effect of different therapeutic combinations not only on
worsening heart failure but also on exercise capacity and left
ventricular function. Thus, the aim of this work was to examine
the combined PROVED and RADIANCE results for poten-
tial differences between triple therapy and other combinations
of ACEI, digoxin and diuretic on a variety of clinical end points
in patients with heart failure due to systolic dysfunction.
Methods
Design of protocols. The PROVED (16) and RADIANCE
(17) trials shared a similar design (Fig. 1). Both studies were
multicenter, double-blind, randomized, placebo-controlled,
parallel group protocols. Each study began with an 8-week
single-blind stabilization phase that patients had to successfully
complete to be eligible for randomization. During this run-in
period, the patients’ background therapy for heart failure,
consisting of digoxin and diuretic in the PROVED trial and
digoxin, diuretic and ACEI in the RADIANCE study, was
optimized. Patients completing this baseline phase were ran-
domized to continue digoxin or to receive placebo instead of
digoxin while trial-specific background therapy was kept con-
stant for as long as possible during follow-up. After random-
ization, patients were reassessed in detail regarding clinical
status, exercise capacity and ventricular function. Patients were
withdrawn from either study for adverse reactions during
follow-up or if their heart failure worsened sufficiently to
require one of the following therapeutic interventions: aug-
mentation in therapy for heart failure, visit to an emergency
room for increasing heart failure or hospitalization for heart
failure.
Abbreviations and Acronyms
ACEI 5 angiotensin-converting enzyme inhibitor
DIG 5 Digoxin Investigators Group
PROVED 5 Prospective Randomized Study of Ventricular
Function and Efficacy of Digoxin
RADIANCE 5 Randomized Assessment of Digoxin and
Inhibitors of Angiotensin-Converting Enzyme
Figure 1. Study schema of the
PROVED and RADIANCE studies.
Following a period of single-blind sta-
bilization, patients were randomized to
continue or discontinue digoxin while
maintaining background therapy as in-
dicated. Treatment failure was deter-
mined by a committee blinded to drug
assignment. ACEI 5 angiotensin-
converting enzyme inhibitor, Chg
Dig 5 investigator change in digoxin
dose, CXR 5 chest x-ray, Echo 5 echo-
cardiogram, ER 5 emergency room,
ETT 5 maximal treadmill exercise test,
HF 5 heart failure, Hx 5 history,
LVEF 5 left ventricular ejection frac-
tion, NYHA 5 New York Heart Asso-
ciation functional class, PE 5 physical
examination, SDC 5 serum digoxin
concentration, Wk 5 week, 6 Min-
Walk 5 6 min walk test.
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Analysis of end points. Data from the PROVED and
RADIANCE trials were combined for purposes of this analysis.
The primary objectives of both PROVED and RADIANCE
were to compare patients randomized to continue or discon-
tinue digoxin with respect to the following end points: 1) rates
of withdrawal due to worsening heart failure, 2) time to
withdrawal and 3) changes in exercise capacity as assessed by
treadmill testing or the 6-min walk test. In the present analysis,
end points 1 and 2 were evaluated and analysis of exercise
capacity was restricted to treadmill data. In addition, we
compared the change in left ventricular ejection fraction from
randomization to the last measured value in the study patients.
Treatment groups. A total of 88 patients in PROVED and
178 patients in RADIANCE completed the single-blind stabi-
lization period and were randomized to continue or discon-
tinue digoxin. For the purposes of this study, the two trial
populations were pooled and reanalyzed according to treat-
ment allocation after baseline characterization and randomiza-
tion. The four patient groups that resulted were 1) those on the
triple therapy of digoxin, diuretic and ACEI (n 5 85), 2) those
on ACEI and diuretic (n 5 93), 3) those on digoxin and
diuretic (n 5 42) and 4) the remainder on diuretic alone (n 5
46).
Statistical methods. Differences between baseline charac-
teristics in the treatment groups were determined according to
the chi-Square test for categorical data and analysis of variance
or Student’s t test for continuous variables. Differences in the
frequency of worsening heart failure in the treatment groups
were assessed by the chi-square test. The Kaplan–Meier life
table technique and the Cox proportional-hazards method
were used to compare time to treatment failure among the
therapeutic groups (22,23). Differences in maximal treadmill
exercise testing and change in left ventricular ejection fraction
during follow-up were compared by nonparametric methods
and Student’s t test, respectively. In the exercise analysis,
treatment failures were assigned the lowest rank and carried
forward while patients who dropped out for other reasons had
their last test result carried forward.
Results
Patient characteristics. Patient characteristics in each of
the four treatment groups were generally similar (Table 1).
Patients in the groups treated with an ACEI covered a greater
distance during the 6-min walk test than groups not on ACEI.
Although this difference reached nominal statistical signifi-
Table 1. Baseline Clinical Characteristics in the Four Therapeutic Groups
Characteristic Digoxin 1 ACEI 1 Diuretic ACEI 1 Diuretic Digoxin 1 Diuretic Diuretic p Value
Sex Male 60 (71%) 76 (82%) 38 (90%) 37 (80%) 0.058
Female 25 (29%) 17 (18%) 4 (10%) 9 (20%)
NYHA class I 3 (4%) 3 (3%) 0.350
II 57 (67%) 67 (72%) 35 (83%) 39 (85%)
III 25 (29%) 3 (25%) 7 (17%) 7 (15%)
Primary etiology IHD 55 (65%) 52 (56%) 25 (60%) 31 (67%) 0.507
Non-IHD 30 (35%) 41 (44%) 17 (40%) 15 (33%)
Age (yr) Mean 62 60 64 64 0.077
SEM 1.1 1.2 2.0 1.8
SDC (ng/ml) Mean 1.1 1.0 1.2 1.1 0.111
SEM 0.03 0.04 0.07 0.06
LVEF (units) Mean 26 28 27 29 0.381
SEM 1.2 1.0 1.4 1.5
CT ratio Mean 0.54 0.53 0.52 .053 0.267
SEM 0.01 0.01 0.01 0.01
History HF (yr) Mean 4.7 3.8 3.7 3.1 0.188
SEM 0.5 0.5 0.5 0.5
Diuretic usage Mean 74 76 79 74 0.973
(mg furosemide) SEM 6 6 16 10
Dose captopril (mg) Mean 76 74 N/A N/A 0.838
SEM 6.7 6.0
Dose enalapril (mg) Mean 16 13 N/A N/A 0.250
SEM 2.1 1.9
Supine systolic BP Mean 126 126 130 125 0.614
(mm Hg) SEM 2.0 1.8 2.4 2.9
Supine pulse Mean 77 77 73 73 0.058
(beats/min) SEM 1.4 1.4 1.8 1.4
Exercise duration (s) Median 510 566 494 540 0.764
6 min walk (feet) Median 1140 1210 1071 1005 0.035
ACEI 5 angiotensin-converting enzyme inhibitor; BP 5 blood pressure; CT 5 cardiothoracic ratio; HF 5 heart failure; IHD 5 ischemic heart disease; LVEF 5
left ventricular ejection fraction; N/A 5 not applicable; NYHA 5 New York Heart Association; SDC 5 serum digoxin concentration at randomization; SEM 5
standard error of the mean. P values reflect results of analysis of variance statistics comparing the four therapeutic groups except for the comparison of ACEI inhibitor
doses which is done by Student’s t test.
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cance (p 5 0.035), duration on maximum exercise testing was
similar in the treatment groups (p 5 0.764). The differences
noted in Table 1 did not appear to affect the comparability of
the treatment groups and must be regarded with caution given
their magnitude and the number of comparisons made.
Treatment failure. Figure 2 depicts the frequency of wors-
ening heart failure in the four treatment groups. The frequency
of treatment failure was greater in diuretic alone compared to
digoxin plus diuretic (p 5 0.039), and there was a strong trend
for treatment failure to be lower in patients with ACEI and
diuretic vs. diuretic alone (p 5 0.080).
Figure 3 plots time to treatment failure in the four thera-
peutic groups. Cox proportional-hazards analysis of the
follow-up data demonstrated that the risk of treatment failure
was significantly greater on diuretic alone (p , 0.001), ACEI
and diuretic (p 5 0.001) or digoxin and diuretic (p 5 0.011)
compared to patients treated with a combination of digoxin,
diuretic and ACEI (Table 2). Further multivariate analysis
demonstrated increased risk of worsening heart failure in other
treatment groups vs. triple therapy after adjustment for left
ventricular ejection fraction, cardiothoracic ratio and heart
failure score determined at randomization (all p , 0.01). A
final multivariate analysis which added to the previous model
gender, supine heart rate and distance walked in 6 min at
baseline, also demonstrated increased risk of worsening heart
failure in other treatment groups vs. triple therapy (all p ,
0.01).
Double therapy was also compared with diuretic alone. The
relative risk of treatment failure was significantly less for
digoxin and diuretic compared to diuretic alone (relative risk
0.41 with a 95% confidence interval of 0.18 to 0.95, p 5 0.035),
and a strong trend was present for less risk of treatment failure
on ACEI and diuretic compared to diuretic alone (relative risk
0.58 with a 95% confidence interval of 0.31 to 1.07, p 5 0.077).
The relative risk of treatment failure did not differ between
patients treated with digoxin and diuretic vs. ACEI and
Figure 2. The frequency of treatment failure is
shown for the four therapeutic groups. Patients
randomized to triple therapy were significantly less
likely to fail compared to any of the other three
groups. Treatment failure did not differ significantly
between double therapy arms. ACEI 1 Diur 5
ACEI and diuretic, Dig 1 Diur 5 digoxin and
diuretic, Diur 5 diuretic, triple 5 digoxin, diuretic
and ACEI. *p , 0.01 compared to all other groups.
Figure 3. Likelihood of deterioration in heart
failure (HF) status in the four treatment groups
as previously defined. Patients receiving triple
therapy were less likely to experience treatment
failure compared to any of the other three groups
(all p , 0.01).
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diuretic (p 5 0.410). The risk of treatment failure was signif-
icantly less for the combined group of double therapy patients
(ACEI and diuretic 1 digoxin and diuretic) vs. diuretic alone
(relative risk 0.52 with a 95% confidence interval of 0.29 to
0.93, p 5 0.027).
Exercise testing. Median changes in maximal treadmill
exercise time during follow-up in the various treatment groups
are shown in Figure 4. After 12 weeks, patients on triple
therapy had a significantly greater change (median 116 s) in
exercise time compared to patients on ACEI and diuretic
(median 227 s, p , 0.001) or diuretic alone (median 296 s,
p , 0.001) but not digoxin and diuretic (median 12 s, p 5
0.134). Exercise capacity was significantly better in the triple
therapy group compared to the combined group of double
therapy patients (ACEI and diuretic 1 digoxin and diuretic,
p 5 0.001). The difference in change in exercise time between
ACEI and diuretic vs. digoxin and diuretic was not significant
after 12 weeks of treatment (p 5 0.221).
Change in ejection fraction. The change in left ventricular
ejection fraction from randomization to the last measured
value for each of the four treatment groups is shown in Figure
5. The change in ejection fraction was higher among patients
who continued digoxin and diuretic than in those patients
treated with triple therapy. Left ventricular ejection fraction
declined significantly in patients withdrawn from digoxin com-
pared to patients who continued digoxin whether ACEI were
included in their regimen.
Discussion
Extensive studies have established the role of ACEI in
reducing morbidity and mortality associated with heart failure,
and the primacy of these agents has been appropriately
emphasized in clinical guidelines for heart failure (4,5). How-
ever, previous findings from the PROVED and RADIANCE
studies combined with recent results from the DIG trial
suggest that the therapeutic role of digoxin in heart failure
should be reassessed (16 –18). Our pooled analysis of
PROVED and RADIANCE results support the concept that
triple therapy with digoxin, diuretic and ACEI may be the most
effective treatment strategy in symptomatic heart failure due to
systolic dysfunction. Patients treated with triple therapy had
the lowest risk of worsening heart failure of any of the four
therapeutic groups in these combined trials. Exercise capacity
was significantly better maintained in patients on triple therapy
compared to diuretic alone or ACEI and diuretic and a trend
toward superiority was found compared to digoxin and di-
uretic. The change in exercise capacity was significantly greater
in triple therapy compared to the combined groups of double
therapy (ACEI and diuretic and digoxin and diuretic). Admin-
istration of triple therapy resulted in better maintenance of left
ventricular ejection fraction compared to regimens that lacked
digoxin. The appearance of improved ventricular function with
digoxin and diuretic therapy relative to triple treatment was
unexpected and seems most likely a chance observation.
Additional data concerning the possibility that ACEI treat-
ment might lessen the positive inotropic effects of digoxin
during chronic therapy would help resolve this issue. The work
of Gheorghiade et al. (24) did not demonstrate such an effect
during immediate treatment. These investigators found that
stroke work index was increased following the acute adminis-
tration of the combination of digoxin and captopril.
Our data point particularly to the inadequacy of diuretic
alone compared to triple therapy. Patients receiving just
diuretic had a high incidence of treatment failure, experienced
a substantial decrease in exercise capacity and had a significant
decline in ejection fraction over 12 weeks of follow-up relative
to triple therapy. Diuretic alone also appeared to be inferior to
either combination of double therapy.
Previous work. To our knowledge, there are no studies that
permit randomized, placebo controlled, double-blind compar-
ison of the efficacy of triple therapy vs. other combinations of
digoxin, diuretic and ACEI. Data from the DIG trial add more
nonrandomized support for triple therapy (18). In this study, a
very high percentage of patients randomized to digoxin or
placebo were taking ACEI (94% to 95%) and most diuretics
(81% to 82%) at baseline. Given this therapeutic background,
patients in the DIG trial were frequently taking either triple
therapy or ACEI and diuretic. Thus, the reduced morbidity in
Figure 4. Changes in maximal exercise duration after 12 weeks.
Patients on triple therapy had significantly better exercise capacity
than patients on diuretic alone (p , 0.001) or on ACEI and diuretic
(p , 0.001), but not compared to patients on digoxin and diuretic (p 5
0.134).
Table 2. Risk of Treatment Failure Relative to Triple Therapy
Treatment Group Hazard Ratio 95% CI p Value
Diuretic alone 10.2 3.45–30.1 , 0.001
ACEI 1 diuretic 5.8 2.02–16.9 0.001
Digoxin 1 diuretic 4.2 1.25–13.8 0.020
Digoxin 1 diuretic vs.
ACEI 1 diuretic
0.410
p Values are based on an unadjusted Cox proportional-hazards analysis.
ACEI 5 angiotensin-converting enzyme inhibitor; CI 5 confidence interval.
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the DIG trial in patients treated with digoxin is consistent with
our findings on the beneficial effects of triple therapy. Several
randomized studies have investigated the relative, short-term
effectiveness of double therapy with ACEI and diuretic vs.
digoxin and diuretic (25–29). Overall, these studies are consis-
tent with our results and appear to support similar short-term
efficacy of digoxin compared to ACEI therapy. In citing these
studies, we wish to emphasize evidence of the therapeutic
efficacy of digoxin. The important and substantial benefits of
ACE inhibition on morbidity and mortality in heart failure
strongly support the routine use of these agents in patients with
symptomatic and symptomatic left ventricular dysfunction and
the use of alternative therapy to block the renin-angiotensin
system in cases of ACEI intolerance.
Mechanism of action. Disparate mechanisms of action
suggest a rationale for combining ACEI and digoxin to im-
prove the clinical status of patients with heart failure as ACEI
do not exert positive inotropic effects. To the extent that
digoxin’s efficacy depends on its inotropic action, additive
salutary effects could be expected when both drugs are admin-
istered. Angiotensin II has complex autonomic effects which
appear to include augmentation of central sympathetic out-
flow, presynaptic and postsynaptic potentiation of peripheral
sympathetic nerve activity and diminution of parasympathetic
tone (8,9). Clinical studies have associated administration of
ACEI with reduction in sympathetic activity and augmentation
of parasympathetic tone (10,11). Recent evidence substanti-
ates a significant sympathoinhibitory effect of digitalis that may
occur at modest serum digoxin concentrations and could be
related to drug efficacy (12–15). Although the neurohormonal
inhibitory actions of ACEI and digoxin might be reduced by
simultaneous administration (16), major sympatholytic effects
of digoxin appear indirect and related to changes in barore-
ceptor function (17). Another rationale for combining digoxin
and ACEI is the tendency for these latter agents to increase
serum potassium which could limit digoxin toxicity.
Limitations. It is not our intention to argue that the
PROVED and RADIANCE trials provide definitive evidence
concerning the efficacy of triple therapy with digoxin, diuretic
and ACEI in patients with heart failure due to systolic dys-
function. Investigation of the relative benefits of triple therapy
was not prespecified as part of the PROVED and RADIANCE
study analyses. The patients were randomized separately into
the two trials so that differences in the study populations may
exist. A number of considerations do, however, lessen the
impact of these concerns. The two trials shared the same
design which supports the pooling of data across the studies.
The various treatment groups were similar at baseline for the
characteristics evaluated. Multivariate analysis, the classical
statistical technique to adjust for baseline characteristics that
might have influenced the likelihood of treatment failure,
confirmed the results obtained by unadjusted lifetable anal-
ysis. Finally, the findings in these two trials related to the
two double therapy groups are consistent with previous
studies.
Utilization of results from the PROVED and RADIANCE
trials to study aspects of the efficacy of digoxin has been
challenged by some investigators because of their withdrawal
design. Interestingly, results from the DIG trial (18) support
the validity of findings from PROVED and RADIANCE
(16,17). In the DIG study, patients withdrawn from digoxin
experienced clinical deterioration while clinical benefit was
evident when randomization resulted in the addition of digoxin
to background therapy.
Conclusion. In patients with severe systolic dysfunction,
triple therapy with digoxin, diuretic and ACEI significantly
reduced the risk of worsening heart failure and improved
exercise tolerance during short-term follow-up compared to
double therapy with diuretic plus ACEI or digoxin or mono-
therapy with diuretic alone. Pending definitive, prospective
clinical trials, our results suggest consideration of triple ther-
Figure 5. Changes in left ventricular ejection fraction
(LVEF) from randomization to final study measurement in
the four treatment groups. Left ventricular ejection fraction
declined significantly in both regimens of digoxin with-
drawal compared to either regimen of digoxin continuation.
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apy as the initial management of patients with symptomatic
heart failure due to severe systolic dysfunction.
The authors gratefully acknowledge the efforts in manuscript preparation
provided by Tyler Joscelyn.
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